Is it anxiety or a panic attack? Discover the key differences and learn why understanding them matters for managing your ...

It’s hard to know how long anxiety disorders will last when you’re in the thick of them. It was during the mid-2000s that my ...

For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring ...

Questions over the extent to which animals can experience mental illness have existed for centuries. Though researchers and ...

The emergency department, while sophisticated and able to treat a variety of medical issues, is not always equipped to ...

Learn how quickly you can expect relief from Klonopin, a benzodiazepine medication commonly prescribed for anxiety and ...

I’ve lived with anxiety disorders for as long as I can remember. My sister has struggled with them too. Looking ...

J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.

Johnson & Johnson strengthens its neuroscience portfolio by acquiring Intra-Cellular Therapies, expanding its focus on CNS ...

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and ...

Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company.

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...